Prophylactic activity of intranasal enviroxime against experimentally induced rhinovirus type 39 infection.

摘要: Intranasal administration of enviroxime by aerosol spray was associated with drug levels in nasal secretions that 1 h later averaged 750-fold higher than those inhibitory for rhinoviruses vitro (0.2 microgram/ml). However, intranasal (one per nostril, five times day) to susceptible volunteers, beginning day before and continuing 4 days after virus exposure, did not significantly reduce infection or illness due experimentally induced rhinovirus type 39 infection. The combined results two separate trials yielded an rate 100% 21 placebo-treated 89% 19 enviroxime-treated subjects. Approximately one-half the volunteers each group had seroconversion challenge virus. Overall, 52% 53% subjects developed colds. No significant differences symptom scores, mucus weights, numbers tissues used were observed between groups. Two-thirds noted irritation immediately sprays, as compared only one-third